title: Survival analysis and prognostic factors for neuroendocrine tumors in Turkey.
abstract: BACKGROUND
  This study aimed to determine the demographical distribution, survival and prognostic factors for neuroendocrine tumors monitored in our clinic.
  
  
  METHODS
  Data for 52 patients who were admitted to Cumhuriyet University Medical Faculty Training Research and Practice Hospital Oncology Center between 2006 and 2012 and were diagnosed and treated for neuroendocrine tumors were investigated.
  
  
  RESULTS
  Of the total, 30 (58%) were females and 22 (42%) were males. The localization of the disease was gastroenteropancreatic in 29 (56%) patients and other sites in 23 (44%). The most frequently involved organ in the gastroenteropancreatic system was the stomach (n=10, 19%) and the most frequently involved organ in other regions was the lungs (n=10, 19%). No correlation was found between immunohistochemical staining for proteins such as chromogranin A, synaptophysin, and NSE and the grade of the tumor. The patients were followed-up at a median of 24 months (1-90 months). The three-year overall survival rate was 71%: 100% in stage I, 88% in stage II, 80% in stage III, and 40% in stage IV. The three-year survival rate was 78% in tumors localized in the gastroenteropancreatic region, and 54% in tumors localized in other organs. In the univariate analysis, gender, age, performance status of the patients, grade, localization, surgical treatment, and neutrophil/ lymphocyte ratio (≤ 5 versus >5) affected the prognosis of the patients.
  
  
  CONCLUSIONS
  Most of the tumors were localized in the gastroenteropancreatic region, and the three-year survival rate in tumors localized in this region was better than the tumors localized in other sites. Surgical treatment was a positive independent prognostic factor, whereas Grade 3 and a neutrophil/lymphocyte ratio of >5 were negative independent prognostic factors.
authors.affiliation: Radiation Oncology Department, Cumhuriyet University School of Medicine, Sivas, Turkey E-mail : yucelbirsen@yahoo.com.
authors.forename: Birsen
authors.initials: B
authors.lastname: Yucel
authors.forename: Nalan Akgul
authors.initials: NA
authors.lastname: Babacan
authors.forename: Turgut
authors.initials: T
authors.lastname: Kacan
authors.forename: Ayfer Ay
authors.initials: AA
authors.lastname: Eren
authors.forename: Mehmet Fuat
authors.initials: MF
authors.lastname: Eren
authors.forename: Seher
authors.initials: S
authors.lastname: Bahar
authors.forename: Mustafa Gurol
authors.initials: MG
authors.lastname: Celasun
authors.forename: Mehmet Metin
authors.initials: MM
authors.lastname: Seker
authors.forename: Zekiye
authors.initials: Z
authors.lastname: Hasbek
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000378:metabolism / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor